NCT05757414 is a NA clinical trial of Tailored Lighting Intervention (LIT) in Parkinson Disease, sponsored by Icahn School of Medicine at Mount Sinai.

Who is sponsoring NCT05757414?

NCT05757414 is sponsored by Icahn School of Medicine at Mount Sinai.

What drugs are being tested in NCT05757414?

Interventions in NCT05757414: Tailored Lighting Intervention (LIT), Actigraph.

What condition does NCT05757414 study?

NCT05757414 studies Parkinson Disease, Sleep Disturbance.

Is NCT05757414 still recruiting?

NCT05757414 is currently completed. Last updated 16 July 2025.

Last reviewed 2025-07-16 · How we verify

NCT05757414

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Lighting Intervention to Improve Sleep

Completed NA Last updated 16 July 2025

What this trial tests

NA trial testing Tailored Lighting Intervention (LIT) in Parkinson Disease in 57 participants. Completed in 30 June 2025.

Timeline

16 November 2021

Primary endpoint
30 June 2025

30 June 2025

Quick facts

Lead sponsor	Icahn School of Medicine at Mount Sinai
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	57
Start date	16 November 2021
Primary completion	30 June 2025
Estimated completion	30 June 2025
Sites	1 location across United States

Drugs / interventions tested

Tailored Lighting Intervention (LIT)
Actigraph

Conditions studied

Parkinson Disease — all drugs for Parkinson Disease →
Sleep Disturbance — all drugs for Sleep Disturbance →

Sponsor

Icahn School of Medicine at Mount Sinai

Who can join

18 and older, any sex, with Parkinson Disease or Sleep Disturbance. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

50 participants with Parkinson's disease will be recruited to complete actigraphy studies to assess sleep disturbances. For this, participants will wear an Actigraph for seven days. Thirty of these participants with sleep disturbance, will go on to receive a tailored lighting intervention (TLI) to assess the effect on sleep, fatigue, and circadian entrainment via urinary melatonin levels.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Supplemental ambient lighting intervention to improve sleep in Parkinson's disease: A pilot trial.
Yoo AS, Wise A, Ortega RA, Raymond D, et al · · 2024 · cited 4× · PMID 39405632 · DOI 10.1016/j.parkreldis.2024.107149

Verify or expand the search:

Other recruiting trials for Parkinson Disease

Currently open trials in the same condition.

NCT07399496 — Accelerated TMS for Apathy in PD · NA · recruiting
NCT07371338 — Phase 1 Clinical Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of IPS101A in Parkinson's Disease Patients · Phase 1 · recruiting
NCT07442370 — The Effect of Functional Rotational Exercises on Fall Risk and Mobility in Parkinson's Disease Patients · NA · recruiting
NCT06848205 — Percept Transitions in FOG and PD · NA · recruiting
NCT07432958 — A Study to Evaluate the Effectiveness of Two Doses of AP-472 as Adjunctive Therapy to Levodopa in Parkinson's Disease (P · Phase 2 · recruiting

Other Icahn School of Medicine at Mount Sinai trials

Trials by the same sponsor.

NCT07094308 — The LIFT-ECHO Last Mile Project · NA · not yet recruiting
NCT07291427 — Chronic Subdural Hematoma Embolization With Detachable Coils · not yet recruiting
NCT07194187 — High Intensity Focused Ultrasound (HIFU) Ablation for Treatment of Prostate Tissue in Bladder Outlet Obstruction · NA · not yet recruiting
NCT07260916 — Minimally Invasive Neuroendoscopic Ultra-Early Targeted ICH Evacuation · NA · not yet recruiting
NCT07487948 — Safety and Biomarker Responses of Delgocitinib (JAK1,2,3/TYK2 Inhibitor) in Central Centrifugal Cicatricial Alopecia and · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05757414 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Icahn School of Medicine at Mount Sinai
Last refreshed: 16 July 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05757414.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing